FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3040893043> ?p ?o ?g. }

• W3040893043 endingPage "144" @default.
• W3040893043 startingPage "143" @default.
• W3040893043 abstract "Background: Ixekizumab (IXE), a high-affinity monoclonal antibody selectively targeting IL-17A, was superior to adalimumab (ADA) at Week (Wk) 24 for simultaneous achievement of ACR50 and 100% improvement from baseline in the Psoriasis Area and Severity Index (PASI 100) (primary endpoint) in patients (pts) with active PsA from SPIRIT-H2H 1 . SPIRIT-H2H had two major secondary endpoints and achieved both: noninferiority of IXE to ADA for ACR50 at Wk 24, and superiority of IXE to ADA for PASI 100 at Wk 24. Objectives: To determine how concomitant conventional synthetic DMARD (csDMARD) use affects safety and efficacy of IXE and ADA in prespecified subgroups defined by biologic monotherapy, concomitant MTX use, and concomitant csDMARD use through Wk 52 in SPIRIT-H2H. Methods: SPIRIT-H2H ( NCT03151551 ) was a 52-week, multicentre, randomised, open-label, assessor-blinded, parallel-group study evaluating the efficacy and safety of IXE versus ADA in adults with PsA and naïve to biologic DMARDs. Patients were required to have active PsA fulfilling Classification for Psoriatic Arthritis (CASPAR) criteria and ≥3/68 tender and ≥3/66 swollen joints, ≥3% plaque psoriasis BSA involvement, no prior treatment with bDMARDs, and with prior inadequate response to ≥1 csDMARD (but not necessarily current treatment with csDMARDs). Randomization (1:1) was stratified by concomitant use of csDMARD and the presence/absence of moderate to severe PsO (baseline: BSA≥10% + PASI≥12, + static Physician’s Global Assessment≥3). Patients (N=566) received IXE/ADA through 52 wks according to the labelled dose dependent on presence/absence of moderate-to-severe PsO. In this prespecified subgroup analysis by presence or absence of csDMARDs, efficacy outcomes through wk 52 were compared between IXE and ADA using logistic regression models and Fisher’s exact tests. Missing data were imputed using non-responder imputation. Results: At baseline, 167 of 283 IXE-treated patients and 169 of 283 ADA-treated patients had concomitant MTX use. Of these, 9.0% (15/167) and 7.1% (12/169) treated with IXE and ADA, respectively, were taking an additional csDMARD (sulfasalazine, cyclosporine, or leflunomide). A significantly greater proportion of patients on IXE versus ADA achieved the primary endpoint or PASI 100 when used as monotherapy or in combination with csDMARD (Figure 1A and 1C). At Wk 52, the proportion of patients achieving ACR50 was not statistically different between IXE and ADA, regardless of monotherapy or concomitant csDMARD use (Figure 1B). A significantly higher proportion of patients achieved MDA on IXE compared to ADA in the monotherapy subgroup (49% vs 33%), while the response rates were similar in both combination subgroups (Figure 1D). These data support consistent ACR50, PASI 100, and MDA response for IXE across all three subgroups. Frequencies of adverse events were similar across the three subgroups for IXE and ADA (Figure 2). Conclusion: As with prior studies, 2,3 consistent efficacy across multiple PsA disease-specific endpoints was observed with IXE in SPIRIT-H2H, regardless of whether IXE was taken as monotherapy or in combination with MTX or another csDMARD. No unexpected safety signals were found for either agent. References: [1]Mease et al, Ann Rheum Dis 2020;79:123-31. [2]Coates et al, RMD Open 2017;3:e000567. [3]Nash et al, RMD Open 2018;4:e000692. Disclosure of Interests: Josef S. Smolen Grant/research support from: AbbVie, AstraZeneca, Celgene, Celltrion, Chugai, Eli Lilly, Gilead, ILTOO, Janssen, Novartis-Sandoz, Pfizer Inc, Samsung, Sanofi, Consultant of: AbbVie, AstraZeneca, Celgene, Celltrion, Chugai, Eli Lilly, Gilead, ILTOO, Janssen, Novartis-Sandoz, Pfizer Inc, Samsung, Sanofi, Anthony Sebba Consultant of: Genentech, Gilead, Lilly, Regeneron Pharmaceuticals Inc., Sanofi, Speakers bureau: Lilly, Roche, Sanofi, Eric Ruderman Consultant of: Pfizer, Amanda Gellett Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Christophe Sapin Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Aubrey Trevelin Sprabery Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Soyi Liu Leage Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Sreekumar Pillai Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Paulo Reis Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Peter Nash Grant/research support from: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead, Janssen, MSD, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, MSD, Novartis, Pfizer Inc, Roche, Sanofi, UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, MSD, Novartis, Pfizer Inc, Roche, Sanofi, UCB" @default.
• W3040893043 created "2020-07-16" @default.
• W3040893043 creator A5009653501 @default.
• W3040893043 creator A5011826741 @default.
• W3040893043 creator A5018869382 @default.
• W3040893043 creator A5033112900 @default.
• W3040893043 creator A5034727243 @default.
• W3040893043 creator A5048999112 @default.
• W3040893043 creator A5071934885 @default.
• W3040893043 creator A5089898372 @default.
• W3040893043 creator A5090569050 @default.
• W3040893043 creator A5090753435 @default.
• W3040893043 date "2020-06-01" @default.
• W3040893043 modified "2023-09-25" @default.
• W3040893043 title "OP0228 EFFICACY AND SAFETY OF IXEKIZUMAB VERSUS ADALIMUMAB (SPIRIT-H2H) WITH AND WITHOUT CONCOMITANT CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARD) IN BIOLOGIC DMARD-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS: 52-WEEK RESULTS" @default.
• W3040893043 doi "https://doi.org/10.1136/annrheumdis-2020-eular.4615" @default.
• W3040893043 hasPublicationYear "2020" @default.
• W3040893043 type Work @default.
• W3040893043 sameAs 3040893043 @default.
• W3040893043 citedByCount "1" @default.
• W3040893043 countsByYear W30408930432021 @default.
• W3040893043 crossrefType "journal-article" @default.
• W3040893043 hasAuthorship W3040893043A5009653501 @default.
• W3040893043 hasAuthorship W3040893043A5011826741 @default.
• W3040893043 hasAuthorship W3040893043A5018869382 @default.
• W3040893043 hasAuthorship W3040893043A5033112900 @default.
• W3040893043 hasAuthorship W3040893043A5034727243 @default.
• W3040893043 hasAuthorship W3040893043A5048999112 @default.
• W3040893043 hasAuthorship W3040893043A5071934885 @default.
• W3040893043 hasAuthorship W3040893043A5089898372 @default.
• W3040893043 hasAuthorship W3040893043A5090569050 @default.
• W3040893043 hasAuthorship W3040893043A5090753435 @default.
• W3040893043 hasBestOaLocation W30408930431 @default.
• W3040893043 hasConcept C126322002 @default.
• W3040893043 hasConcept C16005928 @default.
• W3040893043 hasConcept C203092338 @default.
• W3040893043 hasConcept C2776260265 @default.
• W3040893043 hasConcept C2777011040 @default.
• W3040893043 hasConcept C2777077863 @default.
• W3040893043 hasConcept C2777575956 @default.
• W3040893043 hasConcept C2779384505 @default.
• W3040893043 hasConcept C2779745271 @default.
• W3040893043 hasConcept C2779786854 @default.
• W3040893043 hasConcept C2780132546 @default.
• W3040893043 hasConcept C2780564577 @default.
• W3040893043 hasConcept C535046627 @default.
• W3040893043 hasConcept C71924100 @default.
• W3040893043 hasConceptScore W3040893043C126322002 @default.
• W3040893043 hasConceptScore W3040893043C16005928 @default.
• W3040893043 hasConceptScore W3040893043C203092338 @default.
• W3040893043 hasConceptScore W3040893043C2776260265 @default.
• W3040893043 hasConceptScore W3040893043C2777011040 @default.
• W3040893043 hasConceptScore W3040893043C2777077863 @default.
• W3040893043 hasConceptScore W3040893043C2777575956 @default.
• W3040893043 hasConceptScore W3040893043C2779384505 @default.
• W3040893043 hasConceptScore W3040893043C2779745271 @default.
• W3040893043 hasConceptScore W3040893043C2779786854 @default.
• W3040893043 hasConceptScore W3040893043C2780132546 @default.
• W3040893043 hasConceptScore W3040893043C2780564577 @default.
• W3040893043 hasConceptScore W3040893043C535046627 @default.
• W3040893043 hasConceptScore W3040893043C71924100 @default.
• W3040893043 hasIssue "Suppl 1" @default.
• W3040893043 hasLocation W30408930431 @default.
• W3040893043 hasOpenAccess W3040893043 @default.
• W3040893043 hasPrimaryLocation W30408930431 @default.
• W3040893043 hasRelatedWork W14495360 @default.
• W3040893043 hasRelatedWork W2565883611 @default.
• W3040893043 hasRelatedWork W2701201582 @default.
• W3040893043 hasRelatedWork W2755557905 @default.
• W3040893043 hasRelatedWork W2980594697 @default.
• W3040893043 hasRelatedWork W3040893043 @default.
• W3040893043 hasRelatedWork W3106721720 @default.
• W3040893043 hasRelatedWork W3156762546 @default.
• W3040893043 hasRelatedWork W3208988466 @default.
• W3040893043 hasRelatedWork W4297255709 @default.
• W3040893043 hasVolume "79" @default.
• W3040893043 isParatext "false" @default.
• W3040893043 isRetracted "false" @default.
• W3040893043 magId "3040893043" @default.
• W3040893043 workType "article" @default.